Did Emergent beat or miss consensus estimates last quarter?

What were the key takeaways from Emergent’s earnings call?

What is the market's earnings forecast for Emergent next quarter?

What is Emergent's gross profit margin?

What factors drove the changes in Emergent's revenue and profit?

What is Emergent's latest dividend and current dividend yield?

What does Emergent do and what are its main business segments?

What is the revenue and EPS growth rate for Emergent year over year?

- **Financial Excellence**: 2025 saw 12% EBITDA growth to $205 million, 900 bps gross margin expansion, and net leverage reduced to 1.9x.
- **International Expansion**: Secured $140 million CAD in new MCM contracts with Canada, driving 34% of MCM revenue from international markets.
- **Naloxone Innovation**: FDA-approved multi-use packs and carrying cases maintain market leadership, with 74% consumer preference for the latter.
- **2026 Outlook**: Guided for flat to up commercial revenues, 45-47% gross margin, and $135-155 million adjusted EBITDA, reflecting cautious optimism amid macro challenges.

**【CEO Summary Section】**
- **Transformation Plan Progress**: Achieved adjusted EBITDA of $205 million in 2025, reduced net leverage to 1.9x, and secured $140 million CAD in new multiyear MCM contracts with Canada.
- **MCM Growth**: International sales accounted for 34% of MCM revenue, with deliveries to over 20 countries.
- **Naloxone Innovations**: Introduced 6-count and 24-count multi-use packs, and a carrying case preferred by 74% of consumers. FDA-approved configurations support public health partners.
- **Market Leadership**: Maintained leading market share in nasal naloxone despite Q4 revenue impact from U.S. government shutdown.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Total revenue $149 million, adjusted EBITDA $11 million (8% margin), gross margin 43% (up 300 bps), operating expenses down 10% YoY.
- **Full Year 2025**: Revenue $743 million, adjusted EBITDA up 12% to $205 million, gross margin expanded 900 bps, operating expenses reduced $140 million.
- **2026 Guidance**: Revenue $720-760 million, adjusted EBITDA $135-155 million, targeting 45-47% gross margin. First quarter revenue expected $135-155 million.
- **Financial Strength**: Ended 2025 with $205 million cash, net leverage 1.9x, and operating cash flow up 190% to $171 million.

**【Q&A Highlights】**
- No questions were asked during the Q&A session.

Emergent BioSolutions Inc.(EBS)-20260227-2025 Q4 Earnings call transcript

- **Revenue Beat**: Q3 revenue of $231M (+15% YoY) exceeded guidance, driven by 13% NARCAN unit growth and 4 new MCM contracts.
- **Margin Expansion**: Adjusted EBITDA margin of 38% (vs. 18% prior year), with gross margin improving 200bps to 61%.
- **International Growth**: MCM international sales at 34% of segment revenue, up from mid-teens, with higher gross margins than U.S.
- **Leverage Reduction**: Net debt/EBITDA down to 2x from 3.3x, with $15.8M in share buybacks and $6.9M in bond repurchases.
- **Pipeline Catalysts**: Rocketvax Phase I trial in early 2026; 11 MCM contract modifications year-to-date.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $231 million exceeded guidance by $21 million, driven by 13% sequential growth in NARCAN units and 4 new MCM contract modifications. Year-to-date, MCM international sales represent 34% of segment revenue, up from prior years.
- **Strategic Investments**: Continued focus on AI and biodefense capabilities, with 11 contract modifications secured year-to-date. Gross margin expected to improve in 2026 as international orders scale.
- **Financial Health**: Raised full-year revenue guidance to $775-$835 million (midpoint +$5M) and adjusted EBITDA to $195-$210 million (midpoint +$15M). Net leverage reduced to 2x from 3.3x in Q3 2024.
- **Shareholder Returns**: $15.8 million spent on share buybacks (12-month $50M program) and $6.9M in bond repurchases.

**【CFO Financial Commentary】**
- **Profitability**: Q3 adjusted EBITDA margin of 38%, up 200bps YoY, driven by favorable product mix and cost reductions. Year-to-date adjusted EBITDA of $194 million exceeded prior guidance range.
- **Cash Flow**: Strong collections in Q4 despite government shutdown, with liquidity at $346 million (cash + revolver). Operating cash flow improved 50% YoY.
- **Segment Performance**: MCM revenue up 15% YoY to $231 million, while naloxone revenue grew 9% sequentially. Gross margin improved 200bps to 61%.

**【Q&A Highlights】**
- **International MCM Orders**: 34% of MCM sales year-to-date from recurring contracts with EU and other governments. Gross margin on international sales higher than U.S. due to most-favored-nation pricing.
- **NARCAN OTC & Canada**: Canadian sales variable quarter-over-quarter but growing; U.S. OTC channel stable with $50B opioid settlement funds driving demand.
- **Government Shutdown Impact**: Minimal disruption; BARDA and SNS teams continued operations, securing $29M in international MCM orders during Q3.
- **Rocketvax Collaboration**: Phase I trial for live-attenuated virus vaccine expected in early 2026, targeting next-gen pandemic response.


Emergent BioSolutions Inc. (EBS) Q3 2025 Earnings Call Transcript

- **Revenue Beat & EBITDA Growth**: Q2 revenue of $141M (+$21M vs. guidance), year-to-date EBITDA of $106M. Raised 2025 EBITDA guidance to $175M-$200M.
- **Liquidity & Leverage Improvement**: $367M liquidity (1.9x net leverage vs. 9.9x in Q2 2024), $50M share buyback program.
- **NARCAN Recovery**: 50% Q/Q rebound, 40% international MCM sales, $62.4M BAT contract mod.
- **Cost Efficiency**: 53% YoY expense reduction, 2,300 bps gross margin expansion to 49%.
- **Strategic Growth**: TEMBEXA mpox trials, KLOXXADO formulary access, Ontario $65M supply agreement.

**【CEO Summary Section】**
- Q2 revenue of $141 million exceeded guidance by $21 million, with year-to-date adjusted EBITDA of $106 million.
- Raised 2025 adjusted EBITDA guidance to $175 million-$200 million, up from $150 million-$200 million.
- Liquidity improved to $367 million, with $267 million cash and $100 million undrawn revolver.
- NARCAN sales rebounded 50% Q/Q, driven by stabilization post-distributor disruption.
- International MCM sales accounted for 40% of year-to-date revenue, with $62.4 million BAT and $51.9 million VIG contract mods.
- Launched $50 million share repurchase program, buying 1.1 million shares in Q2.

**【CFO Financial Commentary】**
- Adjusted EBITDA of $29 million (20% margin) vs. -$10 million in Q2 2024, with gross margin improving 2,300 bps to 49%.
- Operating expenses down 53% YoY to $63 million, reflecting cost optimization.
- Net leverage reduced to 1.9x from 9.9x in Q2 2024, with $433 million debt (-45% YoY).
- Full-year 2025 guidance: $765 million-$835 million revenue (narrowed from $700 million-$850 million) and $175 million-$200 million EBITDA.

**【Q&A Highlights】**
- NARCAN pricing stable, with low to mid-single-digit volume growth expected.
- Maintained market leadership with 50%+ public interest share, integrating KLOXXADO into NARCANDirect.
- Q2 SG&A of $26 million seen as sustainable run rate.
- Expect additional MCM contract mods in H2 2025, with focus on TEMBEXA clinical trials for mpox/smallpox.

Emergent BioSolutions (EBS)-6 Aug 25-2025 Q2 Earnings call transcript

- **Turnaround Momentum**: 2025 revenue guidance reaffirmed at $750M-$850M, with net leverage halved to 2.8x, supported by $149M cash and $250M liquidity.
- **NARCAN Recovery**: Q1 revenue decline (due to third-party distributor actions) offset by Q2 unit growth; Ontario 3-year contract ($65M) signals B2B expansion.
- **MCM Growth**: $91M international MCM sales (40% of total), with TEMBEXA shipments and WHO collaboration on mpox vaccine.
- **Financial Strength**: Q1 net income up 656% to $68M, adjusted EBITDA margin 35%, and gross margin 58% (700bps YoY improvement).
- **Strategic Initiatives**: $50M Rocketvax partnership and $65M Ontario contract highlight inorganic growth, with $27M+ MCM orders poised for 2025 recognition.

**【CEO Summary Section】**
- **Turnaround Progress**: Reaffirmed 2025 revenue ($750M-$850M) and adjusted EBITDA ($150M-$200M) guidance, with net leverage reduced to 2.8x from 5.7x in Q1 2024.
- **Cash Position**: $149M cash (including $36.5M from Bayview sale) and $250M liquidity, supporting strategic growth.
- **NARCAN Performance**: Q1 revenue decline due to third-party distributor actions and federal funding delays, but Q2 unit trends improving. Ontario 3-year contract ($65M) and Canada expansion highlight B2B growth potential.
- **MCM Expansion**: $91M international MCM sales (40% of total revenue), with TEMBEXA shipments to U.S. and international markets. Collaborating with WHO on ACAM2000 for mpox in Africa.
- **Strategic Deals**: $50M Rocketvax partnership for U.S. manufacturing and $65M Ontario NARCAN contract.

**【CFO Financial Commentary】**
- **Q1 Financials**: Net income $68M (656% YoY growth), adjusted EBITDA $78M (35% margin), and gross margin 58% (700bps YoY improvement).
- **Cost Efficiency**: $32M operating expense reduction (32% YoY), driven by restructuring and divestitures.
- **Liquidity**: $249M total liquidity (cash + revolver), with $55M debt reduction since Q1 2024.
- **2025 Outlook**: Sequential revenue decline expected in Q2, with profitability improving from Q3 onward.

**【Q&A Highlights】**
- **Tariffs**: U.S./Canada-manufactured MCMs shielded from tariffs; NARCAN device sourced from Europe, but inventory secure.
- **Gross Margin**: Improved due to higher-margin international MCM sales and leaner manufacturing.
- **NARCAN Dynamics**: Q1 decline partially offset by Q2 unit recovery; mid-single-digit market growth driven by B2B and public interest segments.
- **International Orders**: $27M+ incremental MCM sales likely to be recognized evenly across 2025, with potential for further expansion.
- **Stock Repurchases**: $50M program announced, with updates to follow in future earnings releases.

Emergent BioSolutions (EBS)-7 May 25-2025 Q1 Earnings call transcript

- **Financial Turnaround**: 2024 net debt reduced by 21%, adjusted EBITDA up $205M to $183M, and gross margin +1,200bps to 45.7%.
- **2025 Guidance**: Conservative revenue $750M-$850M, EBITDA $150M-$200M, with 48%-51% gross margin target.
- **NARCAN Dominance**: 75% market share, 22M doses distributed, and OTC expansion.
- **Growth Drivers**: KLOXXADO launch Q2 2025, Mpox vaccine WHO EUA pending, and $50M Bavarian Nordic milestone.
- **Risk Management**: 2025 guidance cautious on administration transition, but strong Q1 expected.

**【CEO Opening Remarks】**
- **Transformation Progress**: Completed stabilization phase ahead of schedule, reducing net debt by $156M (21%) to $601M and extending debt maturity to 2029. 2024 saw $130M in operating expense savings and $550M in MCM contract awards.
- **Core Businesses**: NARCAN nasal spray distributed 22M doses in 2024, maintaining 75% market share. MCM portfolio includes $30M in Ebola funding and $50M Janssen settlement.
- **2025 Focus**: Strong first quarter, conservative guidance due to administration transition, and opportunities in KLOXXADO (8mg naloxone) and Mpox vaccine trials.

**【CFO Financial Review】**
- **2024 Results**: Total revenue $1.04B, adjusted EBITDA $183M (vs. -$22M in 2023). Gross margin improved 1,200bps to 45.7%, driven by restructuring and $101M in operating expense reductions.
- **2025 Guidance**: Revenue $750M-$850M, adjusted EBITDA $150M-$200M (midpoint flat vs. 2024). Gross margin targets 48%-51%, reflecting leaner manufacturing.
- **Liquidity**: $200M cash and revolver capacity, positive operating cash flow ($59M in 2024).

**【Business Outlook】**
- **NARCAN**: Anticipates mid-single-digit volume growth, 75%+ market share, and OTC expansion. KLOXXADO expected to launch Q2 2025 via NARCANDirect.
- **MCM Growth**: $550M in 2024 contract wins, including BioThrax (military anthrax vaccine) and TEMBEXA (Ebola). Mpox vaccine EUA pending WHO review.
- **Strategic Initiatives**: $50M Bavarian Nordic milestone payment expected Q1 2025, and R&D pipeline expansion.

**【Q&A Highlights】**
- **NARCAN Pricing**: 2025 guidance reflects 2024H2 stabilization, with 75%+ public interest share. Sensitive to government funding shifts.
- **EBITDA Trajectory**: 2025 may be trough; 2026+ growth driven by MCM contracts, KLOXXADO, and Mpox.
- **KLOXXADO Distribution**: Launching Q2 2025 via existing network, targeting fentanyl overdose scenarios.
- **Mpox Vaccine**: WHO EUA expected soon; no 2025 guidance but potential upside.
- **Contract Visibility**: $550M 2024 wins provide 2025 visibility; Q1 2025 strong due to 2024 momentum.

Actual											0.01	1.98	2.19	3.67	1.53	0.33	-0.36	4.5	0.18	-0.86	-1.27	-0.31	-3.17	-1.06	-0.54	-0.77	0.59	-2.32	1.37	0.05	0.71	0.16	1.06	-0.43
Forecast											0.01	0.6833	2.115	3.1871	1.1486	1.45	2.3483	4.2329	0.125	0.38	-0.0617	0.044	-1.294	-0.6467	-0.2233	-0.1899	-0.98	-1.135	0.1033	-0.5033	0.44	-0.49	-0.12	0.11
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+189.77%	+3.55%	+15.15%	+33.21%	-77.24%	-115.33%	+6.31%	+44.00%	-326.32%	-1958.35%	-804.55%	-144.98%	-63.91%	-141.83%	-305.48%	+160.20%	-104.41%	+1226.23%	+109.93%	+61.36%	+132.65%	+983.33%	-490.91%

EBS

EBS fundamentals

EBS Q4 2025 Earnings

Earnings Call

You can ask Aime

EBS

EBS fundamentals

EBS Q4 2025 Earnings

Earnings Call

EBS Earnings Call Summary for Q4/20255:00 PM on Feb 26, 2026

EBS Earnings Call Summary for Q3/20255:00 PM on Oct 29, 2025

EBS Earnings Call Summary for Q2/20255:00 PM on Aug 6, 2025

EBS Earnings Call Summary for Q1/20255:00 PM on May 7, 2025

EBS Earnings Call Summary for Q4/20245:00 PM on Mar 3, 2025

You can ask Aime